New drug combo aims to control Hard-to-Treat skin lymphoma

NCT ID NCT05956041

Recruiting now Disease control Sponsor: University of Michigan Rogel Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether combining two drugs, pembrolizumab and mogamulizumab, can shrink or control advanced cutaneous T-cell lymphoma (a type of skin cancer) that has returned or not responded to prior therapy. About 23 adults with stage IIB to IVB disease will receive the drugs in 6-week cycles for up to 2 years. The main goal is to see how many patients have a complete response (no detectable cancer) at 6 months.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CUTANEOUS T-CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

mycosis fungoides primary cutaneous T-cell non-Hodgkin lymphoma Sezary syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CUTANEOUS T-CELL LYMPHOMA FUNGOIDES MYCOSIS SEZARY SYNDROME

Contacts and locations

Locations

University of Michigan Comprehensive Cancer Center
RECRUITING

Ann Arbor, Michigan, 48109, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.